Loading
Sangamo Therapeutics, Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Markels John, was filed 06 Jun 2022.
Sangamo Therapeutics, Inc: what insiders have been doing
Every trade that managers of Sangamo Therapeutics, Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Richmond, United States. It was founded in 1995. From 23 October 2025 to 23 October 2026, the disclosure feed for Sangamo Therapeutics, Inc logged 32 filings by 6 insiders.
The flow runs one way only: 2 sales worth €91k, from 2 insiders, and no purchase. Dubois-Stringfellow Nathalie filed the largest sale, €76k, on 23 April 2026, which represents 0.28% of the company's market value.
For context, the typical company on the same exchange (median of 279 companies) published 8 filings over the same period, against 32 filings here. Over the whole record (from 2016), the tally stands at 9 purchases and 79 sales. The 10-K for the year ended 31 December 2025 shows 39.6 m USD of revenue and -122.9 m USD of net income.
Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
466
Thresholds
n/a
Buy Volume
€311,708
9 ops. · all time
Sell Volume
€13M
79 ops. · all time
Who traded when
BuySaleGregory D. Davis1 sale
Nathalie Dubois-Stringfellow1 sale
Since the insiders bought
- -68.6%Entry US$4.14 · Close at T+365 US$1.30
- -68.6%Entry US$4.14 · Close at T+365 US$1.30
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Sangamo Therapeutics, Inc Buy (bullish), based on 2 analysts. Average price target: US$1.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.07
Analyst consensus
2 analystsBuy
US$1.00Target US$1.50(+1927%)US$2.00
Income statement
RevenueUS$39.6M
EBITDA-US$100.4M-254% margin
Net income-US$122.9M-310.8% margin
Valuation
PER (forward)-0.7x
Beta1.30
Balance sheet & cash
Market capUS$30.7M
Total debtUS$26.8M
Free Cash Flow-US$97.3M
Profitability & ownership
ROA-94.4%
% insiders1.8%
% institutions25.8%
Last declaration on 27 May 2026
Declarations466 total
4,036 shares@ US$0.17430.0023% mcap0.2% of flowCommon StockSEC:0001947007-26-000012:0
1,630 shares@ US$0.17430.0009% mcap0.4% of flowCommon StockSEC:0002041855-26-000010:0
345,942 shares@ US$0.25780.28% mcap24.4% of flowCommon StockSEC:0001947007-26-000010:0
69,827 shares@ US$0.25340.056% mcap22.9% of flowCommon StockSEC:0002041855-26-000008:0
5,119 shares@ US$0.473.0% of flowCommon StockSEC:0002041855-26-000004:1
5,119 shares@ US$0.4722.8% of flowCommon StockSEC:0002089213-26-000004:1
12,354 shares@ US$0.471.5% of flowCommon StockSEC:0001947007-26-000004:1
33,637 shares@ US$0.471.2% of flowCommon StockSEC:0001675687-26-000004:1
12,354 shares@ US$0.471.7% of flowCommon StockSEC:0001877368-26-000004:1
666 shares@ US$0.47253.9% of flowCommon StockSEC:0002089213-26-000004:0
832 shares@ US$0.47250.5% of flowCommon StockSEC:0002041855-26-000004:0
2,063 shares@ US$0.47250.3% of flowCommon StockSEC:0001947007-26-000004:0
1,650 shares@ US$0.47250.2% of flowCommon StockSEC:0001877368-26-000004:0
5,291 shares@ US$0.47250.2% of flowCommon StockSEC:0001675687-26-000004:0
36,676 shares@ US$0.39854.6% of flowCommon StockSEC:0001877368-26-000002:0
7,721 shares@ US$0.398538.1% of flowCommon StockSEC:0002089213-26-000002:0
7,721 shares@ US$0.39854.0% of flowCommon StockSEC:0002041855-26-000002:0
36,676 shares@ US$0.39854.0% of flowCommon StockSEC:0001947007-26-000002:0
36,676 shares@ US$0.39854.7% of flowCommon StockSEC:0001779092-26-000002:0
102,950 shares@ US$0.39853.4% of flowCommon StockSEC:0001675687-26-000002:0
578 shares@ US$0.41663.0% of flowCommon StockSEC:0002089213-25-000008:0
723 shares@ US$0.41660.4% of flowCommon StockSEC:0002041855-25-000006:0
2,544 shares@ US$0.41660.3% of flowCommon StockSEC:0001947007-25-000006:0
2,035 shares@ US$0.41660.3% of flowCommon StockSEC:0001877368-25-000007:0
2,544 shares@ US$0.41660.3% of flowCommon StockSEC:0001779092-25-000007:0
25 of 466 declarations
About Sangamo Therapeutics, Inc
Sangamo Therapeutics, Inc. is a U.S.-based genomic medicine company focused on gene therapy, genome engineering, gene regulation, and selected cell-therapy applications. The company is listed in the United States, having traded on Nasdaq under the ticker SGMO and later transitioning to the OTCQB Venture Market in May 2026 after a Nasdaq delisting process. Its headquarters are in Richmond, California, United States.
Founded in 1995 by Edward Lanphier, Sangamo built its scientific identity around proprietary zinc finger technology. Over time, that platform expanded into zinc finger nucleases, gene regulation, in vivo genome editing, and epigenetic modulation. The company positions itself as one of the few developers spanning multiple layers of genomic medicine, aiming to address severe diseases where current standards of care are limited largely to symptom management rather than durable disease modification. For investors, Sangamo is best understood as a clinical-stage biotech with a long scientific track record but no broad commercial franchise.
Read moreShow less
Its pipeline is concentrated in a small number of high-value, high-risk programs. The lead asset is isaralgagene civaparvovec, also known as ST-920, a one-time gene therapy candidate for Fabry disease. In 2025 and 2026, Sangamo reported positive registrational study data and said it was advancing a rolling BLA submission to the FDA under an accelerated approval pathway. The company also highlighted continuing work in neurology, including programs in chronic neuropathic pain and prion disease, as well as presentations on zinc finger epigenetic regulation and modular integrase technologies. This pipeline mix shows Sangamo’s emphasis on rare, severe indications with meaningful unmet medical need.
Sangamo’s business model combines wholly owned assets with partnerships. Historically, the company has worked with major pharmaceutical companies, which has helped validate its platform and diversify funding sources. Its competitive position depends on whether its proprietary genome-engineering know-how can continue to translate into clinically meaningful results, regulatory acceptance, and eventually commercialization. In a crowded field that includes CRISPR-based developers and other gene-therapy players, Sangamo’s differentiation lies in its longstanding zinc finger expertise and its broader genomic medicine toolkit.
Recent corporate highlights include Fabry disease regulatory progress, new pipeline presentations at the 2026 ASGCT annual meeting, and the significant negative event of losing its Nasdaq listing and moving to OTCQB in May 2026. That market change is important for investors because it typically signals weaker liquidity and higher financing risk. Overall, Sangamo remains a highly speculative biotechnology name: scientifically interesting, clinically focused, but still dependent on execution, regulatory milestones, and additional capital to fund operations.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
